(-)-2-Amino-6-Propionamido--4,5,6,7-Tetrahydrobenzothiazole

(-)-2-Amino-6-propionamido-4,5,6,7-tetrahydrobenzothiazole, supplied as the levorotatory enantiomer (IUPAC: (S)-2-amino-6-(propionylamino)-4,5,6,7-tetrahydro-1,3-benzothiazole), possesses a molecular formula of C₁₀H₁₉N₃OS and a formula mass of 229.36 g mol⁻¹. The compound is manufactured as a white to off-white crystalline powder and finds its principal application as a process-related impurity reference marker in the synthesis and quality control of the dopamine D₂/D₃ agonist pramipexole. Because pramipexole bears a propylamino substituent at the 6-position, the propionamido analogue is a known side-product arising from incomplete reduction of acylation intermediates or from oxidative condensation pathways during the final alkylation step. Its availability in high enantiomeric purity—determined by chiral HPLC with a typical enantiomeric excess of ≥99.0%—allows pharmaceutical development teams to meet the identification and quantification thresholds defined in ICH Q3A (R2) and to validate impurity methods compliant with USP <621> and Ph. Eur. 2.2.46.

The free base exhibits a specific optical rotation of [α]_D²⁰ = −61° (c = 1.0, methanol), consistent with the (S) absolute configuration at the chiral carbon bearing the amide side chain. A single endothermic event detected by DSC operation under a nitrogen purge (ASTM E537) records an onset melting temperature of 169 °C and an enthalpy of fusion of 112 J g⁻¹, characteristic of a single crystalline polymorph. During production campaigns, the material is crystallized from isopropanol/water mixtures in glass-lined reactors of 200 L capacity, filtered, and dried under vacuum at 45 °C until loss on drying falls below 0.5%. Typical batch yields range from 5 to 25 kg with a purity profile that, after recrystallization, contains no individual unspecified impurity above 0.10 area-% by HPLC at 280 nm.

What Role Does the Propionamido Group Play in Dopamine Receptor Ligand Design?

The replacement of the basic propylamino moiety of pramipexole with a neutral propionamido function abolishes the high-affinity binding to dopamine D₃ receptors that defines the therapeutic molecule. While (S)-pramipexole binds to the human D₃ receptor with a K_i of 0.5 nM (determined by competitive [³H]spiperone displacement), the propionamido derivative exhibits a K_i value in excess of 1 µM and fails to stimulate [³⁵S]GTPγS binding at concentrations up to 100 µM. Consequently, the compound serves as a negative control in functional selectivity assays and as an inert internal standard during quantitative LC–MS/MS analysis of pramipexole in plasma and microdialysate samples. Its neutral character also reduces the contribution to the background current in electrospray ionization relative to the permanently charged protonated amine of pramipexole, leading to a lower matrix factor when both species are co-eluted from a C18 column under acidic mobile phases (e.g., 0.1% formic acid in water/acetonitrile). From an impurity perspective, any carry-over of the propionamido intermediate into the final active pharmaceutical ingredient must be controlled to a limit of 0.15% w/w, as per the standard qualification threshold for a maximum daily dose of 4.5 mg pramipexole dihydrochloride monohydrate.

Storage stability studies performed at 25 °C/60% RH over 36 months indicate that the crystalline free base undergoes no detectable degradation when kept in double polyethylene bags placed inside fiber drums. Upon exposure to intense light (ICH Q1B option 2, near-UV/visible), the amide band in the IR spectrum at 1628 cm⁻¹ remains unchanged, and the chromatographic purity decreases by less than 0.02 area-%.

Analytical release and stability specifications are summarized below. All methods have been validated in accordance with ICH Q2(R1) guidelines, and the system suitability criteria are verified on each day of use.

The compound is incompatible with strongly alkaline aqueous solutions (pH > 10), which accelerate opening of the thiazole ring. It should not be co-stored with amine-rich substances that can catalyse amide interchange.

Chiral Stationary Phase Selection and Retention Time Variability Across Polysaccharide-Based Columns

Resolution of the (-)-(S)-enantiomer from its (+)-(R)-counterpart is routinely achieved using polysaccharide-based chiral selectors under normal-phase elution. Screening of three commercially available chiral columns—Chiralpak IA (amylose tris(3,5-dimethylphenylcarbamate)), Chiralpak IB (cellulose tris(3,5-dimethylphenylcarbamate)), and Chiralpak IC (cellulose tris(3,5-dichlorophenylcarbamate))—revealed that IA provides the highest enantioselectivity and resolution for this pair of analytes. The recommended analytical method, transferred directly from pramipexole impurity profiling methods, employs a Chiralpak IA column (4.6 × 250 mm, 5 µm) thermostatted at 30 °C, with a mobile phase of n-hexane/ethanol/diethylamine (80:20:0.1, v/v/v) delivered at 1.0 mL min⁻¹. Under these conditions, the (-)-enantiomer elutes first with a retention time of approximately 8.2 min, while the (+)-enantiomer is retained longer (11.5 min), resulting in a resolution of 2.8 and a selectivity factor of 1.42. Injection volumes are kept at 10 µL, and detection is performed at 280 nm, the absorption maximum of the tetrahydrobenzothiazole chromophore.

In routine quality control, system suitability is assessed by six replicate injections of a racemic mixture at 0.1 mg mL⁻¹. The tailing factor for the (-)-enantiomer peak remains below 1.5, and the relative standard deviation of the retention time does not exceed 0.5%. The limit of detection for the undesired (+)-enantiomer is 0.02 µg mL⁻¹, corresponding to 0.02% with respect to a 100 µg mL⁻¹ sample solution, which lies well below the qualification threshold.

Batches that slip outside the enantiomeric purity specification are often traced to incomplete removal of the N-propionyl group during the final deprotection stage of the synthetic route. The chiral method is therefore integrated into in-process control at the penultimate step, where the saponification reaction mixture is analysed after quenching but before crystallisation.

When a client requires a chromatographic profile that distinguishes the propionamido impurity from the despropyl (6-amino) analogue, the IC column offers improved peak symmetry for the more polar degradation product. The systematic shift in retention induced by the neutral amide versus the basic amine is exploited for peak tracking during forced degradation studies.

The substitution of the 6-propylamino group of pramipexole with a propionamido side chain alters several physicochemical parameters critical to method development and formulation. The most prominent change is the loss of basicity: the secondary amine of pramipexole exhibits a calculated pK_a of 9.5, whereas the propionamido analogue remains neutral across the physiological pH range. This abolishes the pH-dependent solubility profile; the free base solubility in water at 25 °C is 0.8 mg mL⁻¹ for the amide, compared with 2.3 mg mL⁻¹ for pramipexole free base. The log D_7.4 value drops from 1.4 (pramipexole) to 0.3 for the amide, consistent with the reduced ability to partition into octanol. In reversed-phase HPLC using a Kinetex C18 column (150 × 4.6 mm, 2.6 µm) with an ammonium acetate ( 10 mM, pH 4.0)/methanol gradient, the relative retention time of the propionamido impurity versus pramipexole is 0.72, allowing straightforward resolution from the main peak and from the propylamino- and despropyl-related impurities. These differences are systematically exploited when the propionamido compound is used as an internal standard, because its lower hydrophobicity ensures baseline separation from the analyte while its UV response factor at 280 nm differs by less than 5% from that of pramipexole, simplifying quantification without response correction factors.

Hydrolytic Degradation Under Accelerated Stability Testing—Amide Bond Cleavage to the 6-Amino Derivative

Despite the inherent solid-state stability of the crystalline form, the propionamido side chain is susceptible to acid-catalysed hydrolysis in solution. Forced degradation following ICH Q1A(R2) reveals that in refluxing 0.1 N hydrochloric acid (pH 1.0, 70 °C) the molecule undergoes pseudo-first-order cleavage to the 2,6-diamino-4,5,6,7-tetrahydrobenzothiazole. The reaction half-life under these conditions is 2.3 hours, monitored by reverse-phase HPLC at 280 nm. At the end of a 6-hour stress period, the area-% of the 6-amino degradation product rises to 86%, and the mass balance evaluated by peak area sums versus the neat standard accounts for 98.2% of the initial mass. The identity of the degradation product is confirmed by high-resolution mass spectrometry (ESI-QTOF) with a [M+H]⁺ ion at m/z 170.0748 (Δ 0.9 ppm from theoretical mass) and by co-injection with an authentic reference of the diamine. In neutral or mildly alkaline conditions (pH 6–8) at ambient temperature, no measurable degradation occurs over 48 hours, which is sufficient for sample preparation sequences in HPLC autosamplers. Any chromatographic method intended for stability-indicating impurity profiling must therefore include a sample diluent that is either neutral (e.g., 50 mM ammonium acetate, pH 6.5) or organic-rich to suppress hydrolysis during the analytical run. This hydrolytic lability is the primary operational boundary: stock solutions in acidic aqueous media must be prepared fresh daily and discarded after 8 hours unless stored at 2–8 °C, where the rate of degradation is reduced by a factor of 12.

In pilot-scale twin-screw wet granulation trials intended to model potential formulation cross-contamination, the amide remained unchanged when pre-blended with common tablet excipients (lactose monohydrate, microcrystalline cellulose, croscarmellose sodium) at a 0.5% drug load and granulated with water. However, a combination with amine-functionalised disintegrants, such as chitosan, led to amide interchange and formation of the 6-amino species during drying at 60 °C over 2 hours, confirmed by LC-MS analysis. This incompatibility precludes any formulation strategy that places the propionamido impurity in prolonged contact with amine-based additives at elevated temperature.